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We demonstrated that the levels of enzymes responsible for the synthesis of glutathione
(GSH) such as glutathione synthase (GSS), glutamate-cysteine ligase-catalytic subunit
(GCLC), and glutathione reductase (GSR) were signiﬁcantly reduced in the red blood cells
(RBCs) isolated from individuals with human immunodeﬁciency virus (HIV) infection and
this reduction correlated with decreased levels of intracellular GSH. GSH content in RBCs
can be used as a marker for increased overall oxidative stress and immune dysfunctions
caused by HIV infection. Our data supports our hypothesis that compromised levels of GSH
in HIV infected individuals’ is due to decreased levels of GSH-synthetic enzymes. The role
of GSH in combating oxidative stress and improving the functions of immune cells in HIV
patients’ indicates the beneﬁt of an antioxidant supplement which can reduce the cellular
damage and promote the functions of immune cells.
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INTRODUCTION
Roughly 34 million people around the world are infected with
human immunodeﬁciency virus (HIV). Since its ﬁrst reporting in
1981, the beginning of an epidemic, 60 million people have con-
tracted HIV and an estimated 30 million have died due to HIV
related causes (World Health Organization, 2010). HIV infec-
tion is associated with a wide range of different opportunistic
infections that are usually the prime suspect for patients’ poor
survival. Among the array of opportunistic infections, one of the
leading life-threatening infection common among HIV positive
individuals with compromised immune system is Mycobacterium
tuberculosis. Especially in developing countries, as many as eighty
percent of people with AIDS are at risk of developing tubercu-
losis (TB) (World Health Organization, 2009). HIV’s primary
targets in vivo are blood monocytes, CD4 T lymphocytes, and
resident macrophages. Due to HIV’s high afﬁnity for infect-
ing and killing CD4+ T lymphocytes, cell-mediated immunity
is drastically lowered. This results in greater probability for
opportunistic infections, primarily M. tuberculosis (Levy, 1993;
Pantaleo et al., 1993; Droge and Holm, 1997; Herzenberg et al.,
1997).
Glutathione (GSH) is a major component involved in the
control andmaintenance of cellular redox state and cellular home-
ostasis (Grifﬁth, 1999). In addition, GSH is also important in
an array of cellular functions such as protein synthesis, trans-
port across membranes, receptor action, and cell growth (Grifﬁth,
1999). As a natural antioxidant, GSH scavenges peroxide species.
Low levels of GSH have been shown to play a role in the apop-
tosis of CD4+ T cells, which is the major pathology of the HIV
infection, therefore signifying the importance of GSH (Levy, 1993;
Pantaleo et al., 1993; Droge and Holm, 1997; Herzenberg et al.,
1997).
Glutathione is produced by almost all cell types and are present
in two forms, reduced (rGSH) and oxidized (GSSG). rGSH is syn-
thesized by two different mechanisms. De novo synthesis of rGSH
occurs in a two-step process mediated by two different enzymes,
glutamate-cysteine ligase (GCL) and glutathione synthase (GSS).
rGSH is also synthesized via the reduction of GSSG by glutathione
reductase (GSR; Staal, 1998). In this study, we went beyond the
innate immune response components and investigated the changes
in the levels of GSH in red blood cells (RBCs) isolated from indi-
viduals with HIV infection. We hypothesized that compromised
levels of GSH inHIV-infected individuals is due to decreased levels
of enzymes that are involved in the synthesis of GSH. Since RBCs
are systemically present in abundance, we tested our hypothesis
by determining the extent to which the levels of GSH-synthetic
enzymes are compromised in RBCs derived from individuals with
HIV infection and correlating decreased levels of GSH-synthetic
enzymes with deﬁciency in the levels of GSH.
MATERIALS AND METHODS
SUBJECTS
The protocol was approved by Institutional Review Board with the
requirement that each volunteer recruited would need to be given
a consent form that described the basis and the procedures of the
study. A signed informed consent from each volunteer that agreed
to participate was obtained. A total of 16 volunteers (eight healthy
subjects and eight individuals with HIV infection) were recruited
for the study. Individuals with HIV infection were recruited from
the FoothillsAIDSproject. Healthy subjectswithoutHIV infection
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or a history of TB were recruited from the staff of Western Uni-
versity of Health Sciences. All HIV-infected volunteers had been
diagnosed with HIV-1, were taking some form of anti-retroviral
treatment, and had CD4+ T-cell counts between 271 and 1415
cells per mm3. Thirty ﬁve milliliters (mL) of blood was drawn
once from both healthy volunteers and individuals with HIV
infection.
ERYTHROCYTE ISOLATION
Red blood cells were isolated fromwhole blood by density gradient
centrifugation with FICOLL-Paque (GE Healthcare, 17-440-02).
RBCs that aggregated as the bottom layer were collected and stored
at−20◦C in a cell lysis/protein storage buffer [20mMTris, 100mM
NaCl (Amresco, N653), 1X protease inhibitor cocktail (Amresco,
M221)] for western blot analysis.
GEL ELECTROPHORESIS AND WESTERN BLOT ANALYSIS IN RBC
LYSATES FROM HEALTHY AND HIV+ SUBJECTS
Total protein content was determined using Coomassie blue col-
orimetric assay (Thermo Scientiﬁc, PI-23200). 200 μg of total
RBC proteins per sample were separated via denaturing polyacry-
lamide electrophoresis (12%). Separated proteins were transferred
to a Polyvinylidene ﬂuoride membrane (GE, PV4HY00010) by
electroblotting. Membranes were blocked for 1 h at room tem-
perature in tris buffered saline with tween 20 (TBST) and
5% non-fat dry milk followed by three washes (15 min for
each wash) in TBST with mild shaking. The membranes were
then incubated with a primary antibody overnight at 4◦C in
TBST with gentle shaking. The primary antibodies used were
mouse anti-human GSS (1:1000, Abcam, ab5513), mouse anti-
human GSR (1:500, Abcam, ab55075), and rabbit anti-human
glutamate-cysteine ligase-catalytic subunit (GCLC; 1:250, Abcam,
ab40929). Following overnight incubation with the primary
antibodies, membranes were washed ﬁve times for 15 min in
TBST with mild shaking. Washed membranes were incubated
with a secondary antibody conjugated with horse radish per-
oxidase, anti-mouse (1:1000, Abcam, ab7064), or anti-rabbit
(1:1000, Abcam, ab72465) in TBST for an hour at room tem-
perature. Membranes were washed again ﬁve times for 15 min
in TBST with mild shaking. Chemiluminescent substrate was
applied to the membranes which were then exposed to an x-
ray ﬁlm (Genemate, F-9024) and developed in a dark room.
Digital images of the immunoblots were captured using a Ver-
sadoc gel imaging system (Bio-rad, 4000 MP). Densitometric
analysis of the images was performed using ImageJ, a free soft-
ware program available from the National Institutes of Health
(http://rsbweb.nih.gov/ij/).
ASSAY OF GSH LEVELS IN RBCs FROM HEALTHY AND HIV+ SUBJECTS
Glutathione concentrations were measured in RBCs isolated from
healthy and HIV+ individuals by spectrophotometry using a
colorimetric assay kit (Arbor Assays, K006-H1). RBCs were sus-
pended in an ice cold 5% 5-sulfosalicylic acid dihydrate solution
(MP Biomedicals, 160001-4924H). Supernatants collected after
centrifugation were analyzed for the total GSH as per the manu-
facturer’s instructions. All GSH measurements were normalized
with total protein concentrations.
STATISTICAL ANALYSIS
Statistical analysis of the data was carried out using GraphPad
Prism 6. The data was analyzed by comparing the means of n = 8
individuals (unless otherwise speciﬁed) using unpaired student’s
t-tests. P ≤ 0.05 was considered statistically signiﬁcant.
RESULTS AND DISCUSSION
Glutathione is a tripeptide made of glutamine, cysteine, and
glycine. In the de novo synthesis of GSH, glutamine is linked to
cysteine by GCL to form -glutamylcysteine (Grifﬁth, 1999). Then
GSS links the dipeptide -glutamylcysteine to glycine to form the
ﬁnal GSH molecule (Grifﬁth, 1999). The GSH redox system plays
a major role in ridding the body of oxidative stress and restor-
ing homeostasis (Grifﬁth, 1999). To elicit antioxidant effects, GSH
is converted to oxidized glutathione (GSSG) by glutathione per-
oxidase (GPx). GSSG can be converted back to GSH by GSR
(Staal, 1998). It is important to note that only free GSH has
antioxidant effects. On the other hand, GSSG lacks antioxidant
functions and is a byproduct of the scavenging activity of GSH
(Staal, 1998; Grifﬁth, 1999). GSH/GSSG ratio should be main-
tained to optimize the GSH redox system. GCL, the rate-limiting
enzyme of GSH synthesis, is composed of a catalytic subunit
(GCLC) and a modulating subunit (GCLM). GCLC is the com-
ponent that performs the amino acid linkage between glutamine
and cysteine, whereas GCLM modulates the activity of GCLC
(Huang et al., 1993).
It has previously been reported that GSH levels in the plasma,
erythrocytes, and peripheral blood mononuclear cells (PBMC)
of HIV+ individuals are compromised (Sbrana et al., 2004; Ven-
ketaraman et al., 2006; Guerra et al., 2011, 2012; Morris et al.,
2012, 2013). The goal of our study is to characterize the causes
for diminished levels of GSH in HIV infected individuals by
determining the extent to which the levels of GCLC, GSS, and
GSR are decreased in RBCs isolated from individuals with HIV
infection compared to healthy subjects. Measurement of GSS
and GCLC revealed a signiﬁcant decrease in the levels of these
enzymes present in RBCs of HIV-infected individuals compared
to healthy subjects (Figures 1 and 2). Both GSS and GCLC are
crucial enzymes that are involved in the catalytic rate limiting
step and second step reaction, respectively, in the biosynthesis
of GSH (Staal, 1998; Grifﬁth, 1999; Morris et al., 2012, 2013).
We also observed a signiﬁcant decrease in the expression of GSR
in RBCs isolated from HIV positive subjects (Figure 3). This
explains the reason for decreased levels of GSH and the conse-
quences related to the GSH deﬁciency such as loss of immune
function observed in HIV patients (Venketaraman et al., 2006;
Guerra et al., 2011, 2012; Morris et al., 2012, 2013). Reduced
expressions of GSH synthesis enzymes in RBCs from individu-
als with HIV infection was accompanied by decreased levels of
total GSH (Figure 4).
HIV+ individuals were also found to have increased lev-
els of TGF-β in their plasma and macrophage supernatants
(Morris et al., 2012). Moreover, TGF-β is known to block the
production of GCLC which leads to decreased GSH synthe-
sis (Morris et al., 2012). HIV-1 transactivator protein (TAT)
decreases the amount of GSH present in mice through the
modulation of GSH biosynthetic enzymes (Choi et al., 2000).
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FIGURE 1 | Quantifying of GSS enzyme levels in Healthy and
HIV-infected subjects. Red blood cell samples were separated from
blood of healthy volunteers and HIV-infected individuals were used for
measurement of GSS, the enzyme that is involved in the second step
of GSH synthesis. Electrophoresis and Western blot were used. There
was a signiﬁcant decrease of GSS in the RBC of HIV-infected individuals
compared to healthy individuals. Data in (A) represents signiﬁcant
difference in the levels of GSS between RBCs isolated from eight
healthy individuals and eight individuals with HIV infection (*p ≤ 0.05).
(B): Illustrates representative images of GSS and their corresponding
GAPDH bands from four healthy subjects and four individuals with HIV
infection.
FIGURE 2 | Quantifying of GCLC enzyme levels in Healthy and HIV-
infected subjects. Red blood cell samples were separated from blood of
healthy volunteers and HIV-infected individuals were used for measurement
of the catalytic subunit of GCLC that is responsible for the linkage between
glutamine and cysteine in the ﬁrst step of GSH synthesis. Electrophoresis
and Western blot were used. GCLC levels were signiﬁcantly lower in the
RBC of HIV-infected individuals compared to healthy subjects. Data in
(A) represents signiﬁcant difference in the levels of GCLC between RBCs
isolated from eight healthy individuals and eight individuals with HIV infection
(*p ≤ 0.05). (B): Illustrates representative images of GCLC and their
corresponding GAPDH bands from four healthy subjects and four individuals
with HIV infection.
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FIGURE 3 | Quantifying of GSR enzyme levels in Healthy and
HIV-infected subjects. Red blood cell samples were separated from
blood of healthy volunteers and HIV-infected individuals were used for
measurement of GSR. GSR converts oxidized glutathione (GSSG) to
glutathione (GSH). The GSR levels in the RBC of HIV-infected individuals
are lower than healthy individuals. Electrophoresis and Western blot were
used. GSR levels in HIV-infected individuals are lower compared to
healthy. Data in (A) represents signiﬁcant difference in the levels of GSR
between RBC isolated from ﬁve healthy individuals and ﬁve individuals
with HIV infection (*p ≤ 0.05). (B): Illustrates representative images of
GSR and their corresponding GAPDH bands from four healthy subjects
and four individuals with HIV infection.
FIGURE 4 | Assay of GSH levels in RBCs from healthy subjects and
individuals with HIV infection. Analysis of total GSH which includes both
free GSH and GSSG indicated signiﬁcantly higher levels of GSH in healthy
individuals compared to HIV positive subjects. Data in Figure 4 represents
signiﬁcant difference in the levels of total GSH between RBCs isolated from
ﬁve healthy individuals and ﬁve individuals with HIV infection (*p=0.05).
TAT also increases free radical production. Therefore, marked
increase in oxidative stress along with increased levels of TGF-
β lead to the compromised levels of GSH synthesis enzymes.
The master transcription factor nuclear factor (erythroid-derived
2)-like 2 (Nrf2) regulates the expression of antioxidant and
phase II-metabolizing enzymes by activating the antioxidant
response element (ARE) and thereby protects cells and tissues
from oxidative stress. The Nrf2 gene binding to the ARE results
in the upregulation of GSH synthesis enzymes such as GCLC,
GCLM, and GSR. New ﬁndings argue that HIV-1-related pro-
teins downregulate Nrf2 expression and/or activity within the
alveolar epithelium, which in turn impairs antioxidant defenses
and barrier function, thereby rendering the lung susceptible
to oxidative stress and injury (Fan et al., 2013). Furthermore,
this study suggests that activating the Nrf2/ARE pathway with
the dietary supplement sulforaphane could augment antioxidant
defenses and lung health inHIV-1-infected individuals (Fan et al.,
2013).
We have previously reported that the virulent laboratory strain
of M. tuberculosis H37Rv is sensitive to GSH at physiological con-
centrations (5 mM) when grown in vitro (Venketaraman et al.,
2005). Thus, GSH has direct antimycobacterial activity, func-
tioning as an effector molecule in innate defense against M.
tuberculosis infection (Venketaraman et al., 2005; Dayaram et al.,
2006). We recently reported that GSH is integral in facilitating
the control of intracellular growth of M. tuberculosis in human
macrophages (Venketaraman et al., 2005; Dayaram et al., 2006;
Morris et al., 2012, 2013). These results further conﬁrm that
GSH has direct antimycobacterial activity and unfolds a novel
and potentially important innate defense mechanism adopted by
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FIGURE 5 | Model illustrating causes for decreased levels of GSH in individuals with HIV infection.
human macrophages to control M. tuberculosis infection. We also
demonstrated that GSH in combination with cytokines such as
IL-2 and IL-12 enhances the functional activity of natural killer
(NK) cells to inhibit the growth of M. tuberculosis inside human
monocytes (Millman et al., 2008; Guerra et al., 2012). Impor-
tantly, data from our most recent studies indicate that GSH
activates the functions of T lymphocytes to control M. tuberculo-
sis infection inside human monocytes (Guerra et al., 2011). These
results indicate that GSH inhibits the growth of M. tuberculosis
by both direct antimycobacterial effects as well as by activat-
ing the functions of immune cells (Venketaraman et al., 2005;
Dayaram et al., 2006; Millman et al., 2008; Guerra et al., 2011,
2012; Morris et al., 2012, 2013). We also reported that the GSH
concentrations were signiﬁcantly lower in macrophages, NK, and
T cells isolated from individuals with HIV infection compared to
healthy subjects (Venketaraman et al., 2006; Guerra et al., 2011,
2012; Morris et al., 2012, 2013). Decreased levels of GSH in
macrophages, NK ,and T cells derived from individuals with HIV
infection was accompanied by diminished control of intracellu-
lar M. tuberculosis infection (Venketaraman et al., 2006; Guerra
et al., 2011, 2012; Morris et al., 2012, 2013). Our group is a pioneer
in reporting that GSH levels were decreased in macrophages, T
cells, and NK cells from individuals with HIV infection and cor-
relating decreased GSH levels with impaired innate and adaptive
immune responses against M. tuberculosis infection (Venketara-
man et al., 2006; Guerra et al., 2011, 2012; Morris et al., 2012,
2013).
In this study we investigated the cause for decreased levels of
GSH in individuals with HIV infection by quantifying the levels of
GSS, GCLC, and GSR in the RBCs derived from healthy subjects
and individuals with HIV infection. The results of the Western
Blot indicate that there is a signiﬁcant difference in the levels
of GSS, GCLC, and GSR between HIV-infected individuals and
healthy individuals, which supports our hypothesis that individu-
als with HIV infection have lower concentrations of enzymes that
are responsible for both de novo synthesis of GSH and conversion
of GSSG to GSH (Figures 1–3). In addition, our results indi-
cate that there is a signiﬁcant decrease in the levels of total GSH
in the RBCs derived from HIV-infected individuals (Figure 4).
Overall, these signiﬁcant ﬁndings indicating lower levels of GSS,
GCLC, and GSR in HIV-infected individuals support our hypoth-
esis and contribute to previous ﬁndings that there are lower
levels of GSH in HIV-infected individuals than healthy individ-
uals (Figure 5). Observations from the current study combined
with our previous ﬁndings strongly suggest that liposomal formu-
lations of GSH can be used as a possible supplement to current
HIV treatments since they can provide complete rGSHmolecules,
bypassing the cellular machinery for GSH production. Liposomal
formulations containing GSH can be more effective in supple-
menting the intracellular rGSH and restoring the immune cell
functions including the antimycobacterial activity inmacrophages
from HIV patients at concentrations lower than NAC (Venke-
taraman et al., 2006; Guerra et al., 2011, 2012; Morris et al., 2012,
2013).
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